A Study On The Mutations Of BRAF Gene In The Tissues Of Non-small Cell Lung Cancer

Objective:We chose patients with non-small cell lung cancer those who have owned surgerytherapy or lesion biopsy to acquire the tumor tissues in this study. Polymerase chainreaction (PCR) was got to expand the BRAF gene to acquire gene’s sequences studied.Over a direct sequencing manner, we can render amplification gene sequence and weighif there had a mutation.In the present study, to investigate the expression of BRAF gene mutation intissues of patients with non-small cell lung cancer, Providing experimental data ifndsnew target for non-small cell lung cancer’ possible molecular targeted therapy；exploration appears to avoid the use of EGFR-TKIs in the treatment of non-small celllung cancer drug resistance, before taking the medicine should be combined with theneed for detection of BRAF gene,and to detect the correlation between the expressionof BRAF gene mutation and gender, age, pathologic types, TNM staging, degree ofdifferentiation，smoking or non-smoking in non-small cell lung cancer.Method:1)Collected the clinical data of190patients with non-small cell lung cancerwithin2011.3-2012.6which have had surgery therapy or lesion biopsy, groupby the patient’s gender, age, pathologic types, degree of differentiation, TNMstaging, smoking or non-smoking.2)Polymerase chain reaction (PCR) and gene sequencing were performed todetect BRAF mutation in190cases of non-small cell lung cancer.3)Analyze BRAF gene mutation and clinical parameters in patients withstatistically significance by the statistical sotfware named SPSS17.(1 Results:1) Mutated BRAF gene mutation detectionBRAF mutation rate was5.26%in190cases of non-small cell lung cancer,wereon Exon15-V600E mutation (c.1799T>A). Male group was2.52%(3/122)，thefemale group was11.5%(7/68). BRAF mutations was6.15%(4/65) in=65-year-olds〉，65-year-olds was4.80%(6/125).Adenocarcinoma group was9.30%(8/86)，Squamous Cell Carcinoma was2.98%(2/67), large cell lung cancer0,0casesof adenosquamous Carcinoma; in the poorly differentiated group was11.11%(7/70)，well differentiated was2.56%(3/120)1/11period was5.54%(3/55)，III/IV period was5.19%(7/135).Smoking group was2.58%(3/116)，non-smoking group was10.45%(7/74).2) the relationship between BRAF gene mutation and the patients with clinicalfeaturesBRAF mutations of tumor tissue was higher in female than male (11.5%vs2.52%，p <0.05), higher non-smoking than in smoking patients (10.45%vs2.58%,p <0.05). higher in the poorly differentiated group than in well differentiated group.BRAF mutations have no significant correlation (P>0.05) with age, pathologic types,TNM staging.Conclusions:1.In patients with non-small cell lung cancer, the incidence of hotspot mutations inBRAF genes is5.26%. The study for patients with non-small cell lung cancermolecular target therapy to explore the potential of new targets, and the need forjoint testing BRAF gene before applying EGFR-TKIs provides experimental data.2.BRAF genes mutation in lung cancer be closely related to gender, degree ofdifferentiation and smoking or not. There is no significant difference among age，pathologic types, TNM staging.